Wang P, Jin SY. Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma. World J Clin Cases 2023; 11(29): 7091-7100 [PMID: 37946760 DOI: 10.12998/wjcc.v11.i29.7091]
Corresponding Author of This Article
Sheng-Yu Jin, PhD, Chief Doctor, Doctor, Library Staff, Department of Hematology, Yanbian University Hospital, No. 1327 Juzi Street, Yanji 133000, Jilin Province, China. jinsy11@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2023; 11(29): 7091-7100 Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.7091
Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
Pei Wang, Sheng-Yu Jin
Pei Wang, Sheng-Yu Jin, Department of Hematology, Yanbian University Hospital, Yanji 133000, Jilin Province, China
Author contributions: Wang P and Jin SY contributed equally to this work; Wang P designed the study; Jin SY contributed to the analysis of the manuscript; Wang P and Jin SY analyzed the data and contributed to the writing of this article.
Conflict-of-interest statement: All author reports have no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng-Yu Jin, PhD, Chief Doctor, Doctor, Library Staff, Department of Hematology, Yanbian University Hospital, No. 1327 Juzi Street, Yanji 133000, Jilin Province, China. jinsy11@163.com
Received: August 21, 2023 Peer-review started: August 21, 2023 First decision: September 4, 2023 Revised: September 12, 2023 Accepted: September 22, 2023 Article in press: September 22, 2023 Published online: October 16, 2023
ARTICLE HIGHLIGHTS
Research background
Daratumumab is a humanized anti-CD38 monoclonal antibody with broad-spectrum killing activity. Related studies have confirmed that Daratumumab can induce the rapid death of multiple myeloma (MM) cells through multiple pathways.
Research motivation
Nowadays, there are many studies on the clinical application of daratumumab in MM treatment, but there are few reviews and analyses, and the safety is still inconclusive.
Research objectives
To investigate the efficacy and safety of Daratumumab in treating multiple myeloma by meta-analysis.
Research methods
A few relevant articles of this subject have been searched from the public databases. The data of the outcome indicators have been extracted from the articles. A meta-analysis has been performed for the pooling results.
Research results
The use of Daratumumab in the patients of multiple myeloma can improve the overall response rate and complete remission rate, and effectively increase the progression-free survival time of patients. It is noteworthy that the use of Daratumumab also increases the risk of neutrophils and thrombocytopenia, which should be noticed during clinical use.
Research conclusions
Daratumumab has a good effect in treating multiple myeloma, but the safety needs to be confirmed by more studies.
Research perspectives
To determine the efficacy indicator and safety indicator of Daratumumab in treating multiple myeloma, and make a meta-analysis of the summary results of the indicators.
